Tisagenlecleucel In Primary CNS Lymphoma

Primary CNS Lymphoma Clinical Trial

Official title: Pilot Study of Tisagenlecleucel, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, in Patients With Primary Central Nervous System Lymphoma

Status Active, not recruiting

Clinical Trial Summary

In this study, is researching the safety of tisagenlecleucel in participants with primary central nervous system lymphoma. .

-The name of the study intervention is tisagenlecleucel.

Clinical Trial Description

This research study is a Pilot Study, which is the first time investigators are examining this intervention in people with primary central nervous system lymphoma.

• The name of the study intervention is tisagenlecleucel. Tisagenlecleucel is an investigational treatment that uses the participants own immune cells, called T cells, to try to kill the cancerous cells

• The research study procedures include screening for eligibility and study treatment including, leukapheresis, evaluations, and follow up visits.

• The study treatment will be one day and participants will be followed for up to 2 years.

• It is expected that about 6 people will take part in this research study ;

Related Conditions & MeSH terms

• Lymphoma
• Primary CNS Lymphoma
• Refractory Primary CNS Lymphoma
• Relapsed Primary CNS Lymphoma

• NCT number: NCT04134117
• Study type: Interventional
• Source: Massachusetts General Hospital
• Status: Active, not recruiting
• Phase: Phase 1
• Start date: December 11, 2019
• Completion date: December 11, 2024